Public Funding for Aten Therapeutics Ltd

Recent research has suggested that the over activation of a receptor on the surface of cancer cells, called the angiotensin-II type I receptor (AT1R), triggers biological signalling pathways that play a role in many cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis. aTen Therapeutics is developing a novel therapeutic antibody that targets and blocks cancer-related signalling mediated by the AT1R in order to treat breast cancer. This project is a vital step in the development of an innovative breast cancer therapy with the potential to become a major new drug to improve the quality and duration of patients' lives.